巴西南部大规模疫苗接种后BNT162b2 mRNA COVID-19疫苗对有症状奥密克戎感染的效果:一项前瞻性检测阴性设计研究
该前瞻性检测阴性病例对照研究在巴西南部托莱多开展,评估BNT162b2疫苗在奥密克戎流行期间对有症状COVID-19的效果。共纳入1758例(586例病例、1172例对照)进行主要分析。两剂疫苗总体调整效果为46.7%(95%CI,19.9%-64.6%),随接种时间延长从7-29天的77.7%下降至≥120天后的不足30%(无统计学意义)。
要点
- 奥密克戎占鉴定变异株>97%,其中BA.1占84.3%、BA.2占12.6%。
- 两剂BNT162b2对有症状COVID-19的调整效果为46.7%(95%CI,19.9%-64.6%)。
- 效果从接种后7-29天的77.7%下降至≥120天后的不足30%(无统计学意义)。
核心结论
- 在相对年轻健康的巴西人群中,两剂BNT162b2对有症状奥密克戎感染提供保护,但保护随时间显著减弱。
- 作者认为这强调在该人群疾病活动波次前需使用变异适应性疫苗进行加强免疫。
研究设计与样本
- 前瞻性检测阴性病例对照研究,在巴西南部托莱多开展,继大规模BNT162b2疫苗接种后实施。
- 纳入条件为年龄≥12岁、2021年11月3日至2022年6月20日期间因急性呼吸道症状在公共卫生系统就诊并接受SARS-CoV-2 RT-PCR检测的患者。
- 共纳入4574例,其中1758例(586例病例、1172例对照)进入主要分析。
- 主要分析评估两剂BNT162b2对有症状COVID-19的效果。
主要发现
- 平均年龄27.7岁,女性占53.8%,90.1%的Charlson合并症指数为零。
- 奥密克戎占所有鉴定SARS-CoV-2变异株的>97%,BA.1和BA.2分别占84.3%和12.6%。
- 两剂疫苗总体调整效果为46.7%(95%CI,19.9%-64.6%),第二剂至症状开始的中位时间为94天(IQR,60-139天)。
- 效果从接种第二剂后7-29天的77.7%下降至≥120天后的不足30%(无统计学意义)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence regarding effectiveness of BNT162b2 mRNA COVID-19 vaccine against Omicron in Latin America is limited. We estimated BNT162b2 effectiveness against symptomatic COVID-19 in Brazil when Omicron was predominant. METHODS: This prospective test-negative, case-control study was conducted in Toledo, Brazil, following a mass COVID-19 vaccination with BNT162b2. Patients were included if they were aged ≥12 years, sought care for acute respiratory symptoms in the public health system between November 3, 2021 and June 20, 2022, and were tested for SARS-CoV-2 using RT-PCR. In the primary analysis, we determined the effectiveness of two doses of BNT162b2 against symptomatic COVID-19. RESULTS: A total of 4,574 were enrolled; of these, 1,758 patients (586 cases and 1,172 controls) were included in the primary analysis. Mean age was 27.7 years, 53.8 % were women, and 90.1 % had a Charlson comorbidity index of zero. Omicron accounted for >97 % of all identified SARS-CoV-2 variants, with BA.1 and BA.2 accounting for 84.3 % and 12.6 %, respectively. Overall adjusted estimate of two-dose vaccine effectiveness against symptomatic COVID-19 was 46.7 % (95 %CI, 19.9 %-64.6 %) after a median time between the second dose and the beginning of COVID-19 symptoms of 94 days (IQR, 60-139 days). Effectiveness waned from 77.7 % at 7-29 days after receipt of a second dose to <30 % (non-significant) after ≥120 days. CONCLUSION: In a relatively young and healthy Brazilian population, two doses of BNT162b2 provided protection against symptomatic Omicron infection. However, this protection waned significantly over time, underscoring the need for boosting with variant-adapted vaccines in this population prior to waves of disease activity. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov number, NCT05052307 (https://clinicaltrials.gov/ct2/show/NCT05052307).
引用
- Rosa RG, Falavigna M, Manfio JL, et al. BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study. Vaccine. 2023. PMID: 37507274. doi:10.1016/j.vaccine.2023.07.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。